Literature DB >> 31488377

Combination of mesenchymal stem cell-conditioned medium and botulinum toxin type A for treating human hypertrophic scars.

Ching-Hsuan Hu1, Yi-Wen Tseng1, Chien-Wei Lee2, Chih-Yung Chiou3, Shiow-Shuh Chuang4, Jui-Yung Yang4, Oscar K Lee5.   

Abstract

BACKGROUND: Both mesenchymal stem cell-conditioned medium (MSC CM) and Botox have demonstrated therapeutic effects for hypertrophic scar (HS). It is unclear whether a synergistic effect occurs when these treatments are used in combination. We aimed to investigate the therapeutic effects of MSC CM and Botox alone when compared with those of a combined regimen on HS.
METHODS: Fibroblasts from human HS were isolated and treated with Dulbecco's modified Eagle's medium (DMEM), MSCCM, or Botox alone or a combination of MSCCM and Botox. We also used an in vivo HS-buried null mice model to investigate the efficacy of combination treatment.
RESULTS: The results demonstrated that the combination of MSC CM and Botox downregulated both mRNA and protein levels of type I collagen, type III collagen, and alpha-smooth muscle actin (α-SMA) in HS fibroblasts. The combined regimen also suppressed fibroblast proliferative activity, increased apoptosis, and displayed significant inhibitory effects on the contractile ability of HS fibroblasts compared to MSC CM, Botox, or DMEM alone. Using an in vivo HS-buried null mice model, significant scar weight reduction, cell apoptosis, and less α-SMA expression were observed from the combined regimen of MSC CM and Botox compared to those from the other groups. The combined regimen also significantly improved arrangement and deposition of collagen fibers.
CONCLUSIONS: This study demonstrates that a combination of MSC CM and Botox exhibited a significant therapeutic effect compared to monotherapy. Clinical translation of this therapy should be further considered.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BOTOX; Combination treatment; Hypertrophic scar; MSCs Conditioned medium

Mesh:

Substances:

Year:  2019        PMID: 31488377     DOI: 10.1016/j.bjps.2019.07.010

Source DB:  PubMed          Journal:  J Plast Reconstr Aesthet Surg        ISSN: 1748-6815            Impact factor:   2.740


  5 in total

1.  Demystifying the long noncoding RNA landscape of small EVs derived from human mesenchymal stromal cells.

Authors:  Chien-Wei Lee; Yi-Fan Chen; Allen Wei-Ting Hsiao; Amanda Yu-Fan Wang; Oscar Yuan-Jie Shen; Belle Yu-Hsuan Wang; Lok Wai Cola Ho; Wei-Ting Lin; Chung Hang Jonathan Choi; Oscar Kuang-Sheng Lee
Journal:  J Adv Res       Date:  2021-11-19       Impact factor: 12.822

2.  Safety and efficacy of botulinum toxin type A in preventing and treating scars in animal models: A systematic review and meta-analysis.

Authors:  Lingfeng Pan; Haiyan Qin; Caihong Li; Liehao Yang; Mingxi Li; Jiao Kong; Guang Zhang; Lianbo Zhang
Journal:  Int Wound J       Date:  2021-08-17       Impact factor: 3.099

Review 3.  Mesenchymal stem cell therapy in hypertrophic and keloid scars.

Authors:  Christine Bojanic; Kendrick To; Adam Hatoum; Jessie Shea; K T Matthew Seah; Wasim Khan; Charles M Malata
Journal:  Cell Tissue Res       Date:  2021-01-02       Impact factor: 5.249

Review 4.  Functional enhancement strategies for immunomodulation of mesenchymal stem cells and their therapeutic application.

Authors:  Byung-Chul Lee; Kyung-Sun Kang
Journal:  Stem Cell Res Ther       Date:  2020-09-14       Impact factor: 6.832

5.  Comparison of Efficacy among Three Dermal Substitutes in the Management of Critical Lower-Limb Wounds: The Largest Biases-Reduced Single-Center Retrospective Cohort Study in Literature.

Authors:  Giuseppe Cottone; Francesco Amendola; Carlo Strada; Maria Chiara Bagnato; Roberto Brambilla; Francesco De Francesco; Luca Vaienti
Journal:  Medicina (Kaunas)       Date:  2021-12-15       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.